Oracle Health Sciences addresses need to analyze clinical trial genomic data
Friday, March 28, 2014
Oracle Health Sciences has launched Oracle Health Sciences InForm Advanced Molecular Analytics. Integrated with Oracle Health Sciences InForm, the solution enables clinical trial managers to systematically and effectively collect, store and analyze genomic data captured in a clinical trial.
The new capabilities help life sciences organizations stratify patients and reduce R&D costs by leveraging targeted drug development approaches and decreasing study size and length. The solution also helps researchers identify new indications and therapies through post-trial, cross-study analysis with molecular data.
Collecting biomarker data typically is a difficult manual effort, aggregating data scattered across spreadsheets, file systems and siloed transaction systems. With Oracle Health Sciences InForm Advanced Molecular Analytics, researchers have consolidated access to both clinical and genomic data for numerous purposes, such as submission or the design of more exploratory translational research studies, including those that can generate petabytes of data from thousands of whole genome sequences.
Life sciences organizations can gain a single, integrated view of genomic, genetic and clinical data, enabling clinical researchers to identify and validate new targets. The solution supports multiple omics modalities and targeted gene panels and can scale to handle hundreds of thousands of whole genomes.
Oracle Health Sciences InForm Advanced Molecular Analytics is deployed as software-as-a-service (SaaS) and is fully integrated with the Oracle Health Sciences InForm Cloud Service. As a comprehensive and commercially available SaaS solution, life sciences organizations avoid the cost and time associated with building and maintaining custom solutions.
“As clinical trial design advances and becomes more targeted, new dynamics emerge in clinical R&D, such as the increasing need to quickly and reliably identify and validate biomarker hypotheses,” said Mukhtar Ahmed, global vice president of product strategy, Oracle Health Sciences.